Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents

  • A High Court battle between Pfizer Inc PFE, its partner BioNTech SE BNTX locked in a dispute with the rival COVID-19 vaccine maker Moderna Inc MRNA over patents for vaccine technology is set to be heard in London next year.
  • In August, Moderna filed patent infringement lawsuits against Pfizer/BioNTech in the U.S. and Germany.
  • Moderna said that Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology, which is critical in creating Moderna's mRNA COVID-19 vaccine.
  • Pfizer and BioNTech said they developed their vaccine independently, rejecting Moderna's patent claims.
  • In its lawsuit, Moderna asked for an undisclosed amount of money damages from Pfizer COVID-19 vaccines sold since March last year
  • The case reached London's High Court for the first time for a preliminary hearing on Thursday, Reuters reported, ahead of a trial due to take place in April 2024.
  • Pfizer and BioNTech sued Moderna in London in September, seeking to revoke two of Moderna's patents concerning its messenger RNA (mRNA) vaccines.
  • CureVac NV CVAC is involved in patent lawsuits with Pfizer and BioNTech in Germany and the U.S. and at London's High Court, where a trial is expected to occur in July 2024.
  • Pfizer and BioNTech filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac.
  • Price Action: MRNA shares are down 5.69% at $162.50, PFE stock is down 0.09% at $42.91, and BNTX shares are down 1.08% at $139.86 during the premarket session on the last check Friday.
  • Photo via Wikimedia Commons
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareSmall CapLegalGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!